Vancouver, British Columbia - BioMark Diagnostics Inc. (BUX:CNX) (FSE: 20B) (BMKDF) is pleased to announce that it has received a grant from NSERC to partner with Dr. Safieddin Safavi-Naeini for further enhancement of its Raman Spectroscopy system.
Rashid Ahmed, President and CEO, comments: “Our goal is to expand the global utility of BioMark’s surface enhanced Raman system by incorporating important technical features that could increase our capability to help transfer data from our worldwide studies. Dr Safavi-Naeini’s team at the University of Waterloo is a perfect group to help BioMark in this critical project.”
Dr. Safieddin Safavi-Naeini, Ph.D. is Professor in the Electrical and Computer Engineering Department and holds NSERC/Blackberry Industrial Research Chair in Intelligent Integrated Radio and Photonics at the University of Waterloo. Dr. Safavi-Naeimi is a leading hardware expert.
BioMark is very thankful for the continued support from the Canadian government.
About National Sciences and Engineering Research Council of Canada (NSERC) Engage Grants
NSERC Engage Grants are intended to foster the development of new research partnerships between academic researchers and companies and supports research and development projects aimed at addressing a company-specific problem.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting Phase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer